• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

    114.72 +0.29 (+0.25%)
    Streaming Delayed Price Updated: 10:35 AM EDT, Jul 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Rhythm Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Q4 Revenue Beat and Narrows Loss ↗
    Via Chartmill
    News headline image
    Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
    Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
    Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology. 
    Via The Motley Fool
    RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
     
    Via Benzinga
    News headline image
    Rhythm Pharmaceuticals's Earnings: A Preview ↗
     
    Via Benzinga
    News headline image
    Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
    Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    $80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
    Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Prediction: These 3 Stocks Will Crush the Market in 2026 ↗
    These stocks all have catalysts on the way that could provide great news for investors. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    This High-Flying Growth Stock Is Hiding in Plain Sight ↗
    This biotech stock is flying under the radar for many investors, but Wall Street loves it. 
    Via The Motley Fool
    News headline image
    Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    The Great Divergence: Why Big Tech Holds the Line While Logistics and Biotech Face a 2026 Reckoning
    As the curtain closes on 2025, the financial landscape presents a tale of two markets. While the S&P 500 (NYSEARCA: SPY) hovers near the historic 7,000-point milestone, fueled by a 19% year-to-date... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
    As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three... 
    Via MarketMinute
    Topics ETFs Economy World Trade
    News headline image
    Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗
    The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management. 
    Via Stocktwits
    News headline image
    The market is filled with gapping stocks in Thursday's session. ↗
    Let's have a look at the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
    Via Chartmill
    News headline image
    Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    These stocks are moving in today's after hours session ↗
    The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
    Via Chartmill
    News headline image
    Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million ↗
    Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
    IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHB 
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals (NASDAQ:RYTM) Reports Mixed Q3 2025 Results ↗
    Rhythm Pharmaceuticals posts mixed Q3 2025 results, missing revenue estimates. Despite the loss, the company highlights strong drug growth and key regulatory milestones for its obesity treatments. 
    Via Chartmill
    News headline image
    Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Monday? ↗
    As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
    Via Chartmill
    News headline image
    Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.